WebFocused on the Future Our robust pipeline is strategically diversified across several therapeutic areas in ophthalmology that represent attractive market opportunities and continued growth potential.
Did you know?
WebMar 6, 2024 · BEDFORD, Mass.– (BUSINESS WIRE)— January 6, 2024 – Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today provided a corporate update on the progress of its key … WebMar 12, 2024 · Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20- 5560161 (State or other jurisdiction …
WebJan 23, 2024 · Item 8.01 Other Events. On January 23, 2024, Ocular Therapeutix, Inc. (the “Company”) announced that it had resubmitted a new drug application (an “NDA”) to the U.S. Food and Drug Administration (the “FDA”) for DEXTENZA™ (dexamethasone insert) 0.4 mg for the treatment of ocular pain occurring after ophthalmic surgery. WebMar 6, 2024 · Top-Line Data from Phase 2 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2024...
WebApr 10, 2024 · Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. WebOCULAR THERAPEUTIX, INC. (Exact Name of Registrant as Specified in Its Charter) 2014 Employee Stock Purchase Plan (Full Title of the Plan) Antony Mattessich President and …
WebJun 8, 2024 · BEDFORD, Mass., June 08, 2024 -- ( BUSINESS WIRE )--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of …
WebMar 11, 2024 · Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 24 Crosby Drive Bedford, MA 01730 (Address of principal executive offices) (Zip Code) (781) 357-4000 can russian missiles reach usaWebCompany profile page for Ocular Therapeutix Inc including stock price, company news, press releases, executives, board members, and contact information can russian economy surviveWebFeb 12, 2024 · BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix ™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced its intention to present data from its Phase 1 clinical trial of OTX-TKI, an … flannel and tube topsWebInterim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Glaucoma. Learn More About Phase 1 Clinical Trial. ... Ocular Therapeutix, Inc. maintains … Ocular Therapeutix makes no representations or warranties with … Pipeline - Ocular Therapeutix DEXTENZA provides an opportunity for physicians to alleviate their patients of … Careers - Ocular Therapeutix About Wet Age-Related Macular Degeneration. Age-related macular … Data on file 018. Ocular Therapeutix, Inc. 6. Messmer EM. Dtsch Arztebl Int. … ReSure Sealant is indicated for intraoperative management of clear … Information Request - Ocular Therapeutix At Ocular Therapeutix, the company values are embodied in the work we do and … flannel animals how to makeWebOCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware . 001-36554 . 20-5560161 (State or Other Jurisdiction of Incorporation) … flannel and yoga pantsWebApr 14, 2024 · BEDFORD, Mass., April 14, 2024--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ... flannel app with noomaWebJan 3, 2024 · The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: intraocular pressure increased (3%), lacrimation increased (1%), eye discharge (1%), and visual acuity … flannel apron for women